Who We Are
Our Company
Quest PharmaTech is a publicly traded (QPT:TSXV), Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies. Quest is developing an antibody, Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications.
INVESTEE COMPANIES.
- OncoQuest transferred its immunotherapy assets to OQPBIO M through a series of transactions resulting in owning shares of OQPBIO M. Quest now own about 26% of OQPBIO M, the Korean company that is developing immunotherapy assets.
- Quest has an 10.67 % direct ownership interest in OncoVent. Quest also has a 12% indirect interest through its ownership interest in OncoQuest. OncoQuest owns 29% of OncoVent.
